Floatz logo

vb15010

Prostatic Cancer

Zhejiang Yangli Pharmaceutical Technology Co., Ltd.Phase 1/2Active
CC
47/ 100
Provisional rating · Methodology v0.2

Rating breakdown

Clinical Evidence
33/ 100
Competitive Position
89/ 100

Competitive context

513 Active assets in the Prostatic Cancer cohort.

Asset / SponsorPhaseRating
Avodart
Bay State Clinical Trials, Inc.
Phase 4BBB
Desflurane
Peter MacCallum Cancer Centre, Australia
Phase 4BBB
Degarelix
Bayer
Phase 4BBB
PROPOFOL
Peter MacCallum Cancer Centre, Australia
Phase 4BBB
VIPIVOTIDE TETRAXETAN
Novartis Pharmaceuticals
Phase 4BB

View all 50 →

Same molecule, other indications

vb15010 is also rated in:

biliary tract cancerDormant
CCC
Indicative ·
48 / 100
View asset →
breast cancerDormant
CCC
Indicative ·
48 / 100
View asset →
ovarian neoplasmDormant
CC
Indicative ·
43 / 100
View asset →

Need depth?

Order a full diligence report on this asset.

Order report →

Are you the sponsor?

Submit your data room for a Verified Rating. The public-data rating remains visible alongside.

Contact →